Literature DB >> 4393372

Comparative trial of serotonin antagonists in the management of migraine.

J W Lance, M Anthony, B Somerville.   

Abstract

The effectiveness of five different serotonin antagonists in the prevention of migraine was compared in 290 patients followed for periods of up to three years. Methysergide 3-6 mg. daily was most effective, with 20% of treated patients becoming headache-free and a further 44% remaining more than "half improved." The corresponding figures for BC105 were 10% and 40%, respectively.The results with BC105 were significantly better than those with placebo (P<0.02). The total improvement rates with methdilazine (45%) and cyproheptadine (43%) were better than those with placebo (32%) but did not achieve statistical significance. A new preparation, methylergol carbamide maleate, which is chemically related to methysergide, did not give better results than placebo.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4393372      PMCID: PMC1700164          DOI: 10.1136/bmj.2.5705.327

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  13 in total

1.  Studies on headache. The mode of action of UML-491 and its relevance to the nature of vascular headache of the migraine type.

Authors:  D J DALESSIO; W A CAMP; H GOODELL; H G WOLFF
Journal:  Arch Neurol       Date:  1961-03

2.  An antaminic drug, BC 105, in the prophylaxis of migraine. Pharmacological, clinical, and therapeutic experiences.

Authors:  F Sicuteri; G Franchi; P L Del Bianco
Journal:  Int Arch Allergy Appl Immunol       Date:  1967

3.  Studies in vascular permeability of human skin bradykinin.

Authors:  P J Feher; F Kalz
Journal:  Dermatologica       Date:  1966

4.  Clinical trial of a new serotonin antagonist, BC105, in the prevention of migraine.

Authors:  J W Lance; M Anthony
Journal:  Med J Aust       Date:  1968-01-13       Impact factor: 7.738

5.  Indomethacin in migraine.

Authors:  M Anthony; J W Lance
Journal:  Med J Aust       Date:  1968-01-13       Impact factor: 7.738

6.  Double-blind crossover comparison of bc-105, methysergide and placebo in the prophylaxis of migraine headache.

Authors:  R E Ryan
Journal:  Headache       Date:  1968-10       Impact factor: 5.887

7.  Plasma serotonin in migraine and stress.

Authors:  M Anthony; H Hinterberger; J W Lance
Journal:  Arch Neurol       Date:  1967-05

8.  Serotonin, the carotid body, and cranial vessels in migraine.

Authors:  J W Lance; M Anthony; A Gonski
Journal:  Arch Neurol       Date:  1967-05

9.  Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects.

Authors:  D A Curran; H Hinterberger; J W Lance
Journal:  Brain       Date:  1965-12       Impact factor: 13.501

10.  The effect of 5-hydroxytryptamine on the cotton pellet local inflammatory response in the rat.

Authors:  J R Bianchine; N R Eade
Journal:  J Exp Med       Date:  1967-03-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Current concepts in the pathogenesis and interval treatment of migraine.

Authors:  M Anthony; J W Lance
Journal:  Drugs       Date:  1972       Impact factor: 9.546

Review 2.  5-HT2 receptor antagonists and migraine therapy.

Authors:  E J Mylecharane
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

3.  Effects of ergotamine and methysergide on blood platelet aggregation responses of migrainous subjects.

Authors:  B P Hilton; K J Zilkha
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-05       Impact factor: 10.154

4.  Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial.

Authors:  J D Gomersall; A Stuart
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-08       Impact factor: 10.154

Review 5.  Pizotifen (BC-105): a review of its pharmacological properties and its therapeutic efficacy in vascular headaches.

Authors:  T M Speight; G S Avery
Journal:  Drugs       Date:  1972       Impact factor: 9.546

6.  Influence of pizotifen and ergotamine on the venoconstrictor effect of 5-hydroxytryptamine and noradrenaline in man.

Authors:  W H Aellig
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Inhibition of insulin secretion from the perfused pancreas of the rat by pizotifen.

Authors:  H G Joost
Journal:  Br J Pharmacol       Date:  1979-10       Impact factor: 8.739

8.  An assessment of platelet aggregation induced by 5-hydroxytryptamine.

Authors:  B P Hilton; J N Cumings
Journal:  J Clin Pathol       Date:  1971-04       Impact factor: 3.411

9.  Receptors for 5-hydroxytryptamine and noradrenaline in rabbit isolated ear artery and aorta.

Authors:  E Apperley; P P Humphrey; G P Levy
Journal:  Br J Pharmacol       Date:  1976-10       Impact factor: 8.739

10.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.